Summary Background The Cutaneous Lupus Erythematosus Disease Area and Severity
Index (CLASI) is a reliable outcome measure for cutaneous lupus erythematosus (CLE) in …

Background In 2005, a scoring system (CLASI, Cutaneous Lupus Erythematosus Disease
Area and Severity Index) was developed for patients with cutaneous lupus erythematosus …

This study summarizes the use, since its inception, of the Cutaneous Lupus Disease Area
and Severity Index (CLASI) as an outcome measure in clinical studies. We systematically …

Objective To determine the measurement properties of the Cutaneous Lupus Erythematosus
Disease Area and Severity Index (CLASI) and the paediatric adaptation of the Skindex29 …

Objective To evaluate the validity of the Cutaneous Lupus Erythematosus Disease Area and
Severity Index (CLASI) for use by rheumatologists via reliability testing, and to extend the …

Objective To determine how to use the Cutaneous Lupus Erythematosus Disease Area and
Severity Index (CLASI) to classify patients according to disease severity (mild, moderate …

We developed and validated a measurement instrument (CLASI—Cutaneous Lupus
Erythematosus Disease Area and Severity Index) for lupus erythematosus that could be …

Cutaneous lupus erythematosus (CLE) is a clinically heterogeneous group of rare skin
diseases that only rarely have been subjected to controlled clinical trials. This may have …

Skin involvement is a frequent presenting manifestation of systemic lupus erythematosus
(SLE). Cutaneous lupus erythematosus (CLE), frequently occurring without SLE, may be …

Objective To assess the clinical responsiveness of the CLASI (Cutaneous Lupus
Erythematosus [CLE] Disease Area and Severity Index). Design Validation cohort. Setting …